Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mindray to Acquire 75% Stake in DiaSys

By LabMedica International staff writers
Posted on 04 Aug 2023

Mindray (Shenzhen, China) has agreed to acquire a 75% equity interest in DiaSys Diagnostic Systems GmbH (Holzheim, Germany) through its Dutch subsidiary for an all-cash preliminary purchase price of approximately EUR 115 million with the final amount to be determined as of closing. More...

The agreement is slated to be finalized later this year, pending regulatory approvals and the granting of regulatory approvals. Upon finalizing the transaction, Mindray will hold a 75% stake in DiaSys and consolidate DiaSys and its subsidiaries. DiaSys's wide range of clinical chemistry systems, manufacturing capabilities for controls and calibrators, and a global network of manufacturing and distribution sites synergize fully complement Mindray's extensive hematology and immunoassays product range, creating a plethora of market opportunities.

Recognized globally, DiaSys has over 30 years of experience in the in-vitro diagnostics (IVD) field with production facilities spread across Europe, APAC, and Latin America. Mindray intends to utilize DiaSys's international team of professionals and global supply platforms to expedite the construction of overseas supply chains, aiming for further expansion into global medium to large volume customer segments and delivering more timely and comprehensive professional services to clients. Moreover, DiaSys's vast experience in clinical chemistry is anticipated to bring synergistic value to Mindray's IVD business. DiaSys’s expertise in developing and producing IVD controls and calibrators will complement Mindray’s IVD product line and enhance its system performance.

“We are very pleased to see this collaboration come to fruition, as Mindray’s and DiaSys’ businesses strongly complement each other,” said Wu Hao, President of Mindray. “Through this acquisition, Mindray will effectively improve its overseas supply chain platform and support the penetration of our IVD business in the medium to large customer segments. We look forward to both parties jointly realizing synergies and creating greater value for our customers.”

“DiaSys with its comprehensive range of products and global manufacturing footprints, and Mindray with its total IVD solutions and worldwide network, are ideal partners for lifting synergies in the IVD field,” added Dr. Günther Gorka, DiaSys’s Founder. “The individual strengths of both partners will support each other and help for a common and sustainable success in all regions of the world.”

Related Links:
Mindray
DiaSys Diagnostic Systems


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.